 |
197 Diseases |  |
398 Trials |
|
398 Trials |  |
21826 News |  |
| «12...2021222324252627282930...266267» |
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
DOUBLE TROUBLE: IMMUNOTHERAPY INDUCED MYOCARDITIS AND MYOSITIS (Hall B4-5) - Jan 26, 2024 - Abstract #ACC2024ACC_4947;
Timely intervention with high-dose steroids, IVIG, and mycophenolate may mitigate adverse outcomes. Additional research is needed for risk assessment and exploring the role of early mechanical circulatory support in managing such cases.
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
A RARE PRESENTATION OF A COMMON PROBLEM: CARDIAC TAMPONADE IN A PATIENT WITH POORLY DIFFERENTIATED MALIGNANT NEOPLASM WITH BASALOID FEATURES AND PROMINENT DESMOPLASTIC STROMA IN THE ANTERIOR MEDIASTINUM (Hall B4-5) - Jan 26, 2024 - Abstract #ACC2024ACC_4927;
Additional research is needed for risk assessment and exploring the role of early mechanical circulatory support in managing such cases. To our knowledge, this is the first description of cardiac tamponade related to a poorly differentiated malignant neoplasm with basaloid features and prominent desmoplastic stroma.
- AN UNSUSPECTING CULPRIT OF CANCER TREATMENT INDUCED CARDIOMYOPATHY (Hall B4-5) - Jan 26, 2024 - Abstract #ACC2024ACC_3322;
Background: Novel treatment agents have revolutionized melanoma treatment, but distinguishing their cardiotoxicities in clinical practice is challenging.Case: 41-year-old man with metastatic melanoma, previously treated with nivolumab / ipilimumab, then encorafenib / binimetinib, most recently pembrolizumab / lenvatinib 2 weeks prior, presented with acute systolic heart failure with ejection fraction (EF) of 20%, in cardiogenic shock requiring mechanical support. As targeted cancer therapies with cardiotoxicity risks become more common, cardiologists must be able to quickly recognize and differentiate the culprit agent.
- Erleada (apalutamide) / J&J, Yervoy (ipilimumab) / Ono Pharma, BMS
THE BURDEN OF SUBCLINICAL CORONARY ARTERY DISEASE AS MEASURED BY CORONARY ARTERY CALCIFICATION AND ASSOCIATION WITH LEPTIN LEVELS IN PATIENTS WITH METASTATIC PROSTATE CANCER (Moderated Poster Theater 09) - Jan 26, 2024 - Abstract #ACC2024ACC_3195;
In this study of men with mCRPC, higher leptin levels were associated with RCA atherosclerosis independently of traditional cardiac risk factors. These findings support the hypothesis that a subset of CAD and prostate cancer patients share a biologic vulnerability, functionally linked by adiposity and leptin.
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
METASTATIC MELANOMA INITIALLY PRESENTING AS ISCHEMIA ON CARDIAC STRESS TESTING - A RARE PRESENTATION (Moderated Poster Theater 12) - Jan 26, 2024 - Abstract #ACC2024ACC_2449;
Malignant melanoma is an aggressive tumor with cardiac involvement manifesting in the form of ischemic and electrical abnormalities. Malignant melanoma first presenting as cardiac ischemia is rare, thus clinicians should be aware of possibility of metastatic cardiac melanoma in patients presenting with ischemia or electrical abnormalities prompting early detection and treatment .
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
METASTATIC MELANOMA OF THE HEART TREATED WITH IMMUNOTHERAPY (Hall B4-5) - Jan 26, 2024 - Abstract #ACC2024ACC_838;
Despite his poor prognosis, the patient was treated with ICI's, ipilimumab and nivolumab, with near resolution of his cancer.Decision?making: Given the patients poor prognosis, deciding to start the patient on trial immunotherapy vs palliative care was most challenging. Despite its cardiac toxicity, ICI's can dramatically increase the survival rate of patients who are afflicted with metastatic melanomas, particularly when the heart is involved.
- Remicade (infliximab) / J&J, Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
COMPLETE HEART BLOCK IN A PATIENT UNDERGOING COMBINATION IMMUNE CHECKPOINT INHIBITOR THERAPY (Hall B4-5) - Jan 26, 2024 - Abstract #ACC2024ACC_281;
However, CHB is less often documented. Our goal is to raise clinical awareness given the few cases describing complete AV block within this population.
- ||| Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
P3 data, Journal, HEOR: Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial. (Pubmed Central) - Jan 25, 2024
Our goal is to raise clinical awareness given the few cases describing complete AV block within this population. With the longest follow-up available to date in melanoma patients with asymptomatic brain metastases, the NIBIT-M2 study continues to show persistent therapeutic efficacy of I ipilimumab plus nivolumab while preserving HRQoL.
- | Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal: First-line nivolumab plus ipilimumab with or without chemotherapy for Japanese patients with non-small cell lung cancer: LIGHT-NING study. (Pubmed Central) - Jan 25, 2024
With the longest follow-up available to date in melanoma patients with asymptomatic brain metastases, the NIBIT-M2 study continues to show persistent therapeutic efficacy of I ipilimumab plus nivolumab while preserving HRQoL. LIGHT-NING offers valuable insights into combination immunotherapy for untreated patients with stage IV or recurrent non-small cell lung cancer in Japanese real-world settings.
- | Yervoy (ipilimumab) / BMS
Trial completion date: Ipilimumab for Head and Neck Cancer Patients (clinicaltrials.gov) - Jan 25, 2024
P1, N=18, Active, not recruiting, Sponsor: Providence Health & Services
LIGHT-NING offers valuable insights into combination immunotherapy for untreated patients with stage IV or recurrent non-small cell lung cancer in Japanese real-world settings. Trial completion date: Nov 2023 --> Dec 2024
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Sinonasal melanoma patterns of care and outcomes in the contemporary therapeutic era: a high-volume single institution experience (JW Marriott Desert Ridge Grand Canyon 6-8; Poster Screen #1) - Jan 24, 2024 - Abstract #MHNCS2024MHNCS_269;
In the setting of progression on neoadjuvant Ipi/Nivo, one patient proceeded to RT followed by 6 cycles of Carboplatin/Paclitaxel...However, pts who responded to upfront Ipi /Nivo had significantly better outcomes. Further studies are needed to improve response rates to neoadjuv ant therapy and improve overall outcomes.
- relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
A phase II trial of personalized immunotherapy in patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M HNSCC) that have progressed on prior immunotherapy. (JW Marriott Desert Ridge Grand Saguaro Ballroom) - Jan 24, 2024 - Abstract #MHNCS2024MHNCS_84;
Further studies are needed to improve response rates to neoadjuv ant therapy and improve overall outcomes. If the CTLA4 vs LAG3 RRS difference was > 15.2, pts were
- || Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
P2b data, Journal, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker, Metastases: Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial. (Pubmed Central) - Jan 24, 2024
P2b
The addition of ipi/nivo to chemotherapy increased toxicity without improving efficacy. Ipi/nivo administered sequentially to chemotherapy was tolerable and induced clinical responses.
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion date, Trial primary completion date: KRAS-Targeted Vaccine With Nivolumab and Ipilimumab for Patients With NSCLC (clinicaltrials.gov) - Jan 24, 2024
P1, N=12, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Ipi/nivo administered sequentially to chemotherapy was tolerable and induced clinical responses. Trial completion date: Apr 2026 --> Apr 2027 | Trial primary completion date: Apr 2024 --> Apr 2025
- | Yervoy (ipilimumab) / BMS
Phase classification, Combination therapy: Ipilimumab and Local Radiation for Selected Solid Tumors (clinicaltrials.gov) - Jan 24, 2024
P1, N=3, Terminated, Sponsor: Stanford University
Trial completion date: Apr 2026 --> Apr 2027 | Trial primary completion date: Apr 2024 --> Apr 2025 Phase classification: P1/2 --> P1
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion date, Trial primary completion date, IO biomarker: CA209-324: An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma (clinicaltrials.gov) - Jan 23, 2024
P2, N=50, Recruiting, Sponsor: Dana-Farber Cancer Institute
Phase classification: P1/2 --> P1 Trial completion date: Jun 2024 --> Sep 2025 | Trial primary completion date: Dec 2023 --> Mar 2025
- || Review, Journal: Advances and challenges of first-line immunotherapy for non-small cell lung cancer: A review. (Pubmed Central) - Jan 23, 2024
Results from first-line trials have shown that almost all driver-negative mNSCLC are treated with ICIs and significantly prolong patient survival; however, the low response rate and adverse reactions to immunotherapy remain to be addressed. Here, we summarize the use of ICIs, including monotherapy and combination therapy, in the first-line treatment of mNSCLC in recent years and discuss the low response rate and adverse reactions of ICIs as well as the challenges and expectations for the first-line treatment of mNSCLC in the future.
- ||| Yervoy (ipilimumab) / Ono Pharma, BMS
Retrospective data, Review, Journal, Adverse events, Checkpoint inhibition: Incidence of Cutaneous Immune-Related Adverse Events and Outcomes in Immune Checkpoint Inhibitor-Containing Regimens: A Systematic Review and Meta-Analysis. (Pubmed Central) - Jan 23, 2024
Higher incidence of cirAEs was associated with ICI combination regimens and with CTLA-4-containing regimens, particularly with higher doses of ipilimumab, as compared to PD-1/L1 monotherapies...Overall survival was positively correlated with the incidence of pruritis, vitiligo, and rash; this association was significant for vitiligo (p = 0.0483). Our analysis provides benchmark incidence rates for cirAEs and links cirAEs with favorable treatment outcomes at a study level across diverse solid tumors and multiple ICI regimens.
- || LY3321367 / Eli Lilly, Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Review, Journal, MSi-H Biomarker, PD(L)-1 Biomarker, IO biomarker: Beyond PD(L)-1 Blockade in Microsatellite-Instable Cancers: Current Landscape of Immune Co-Inhibitory Receptor Targeting. (Pubmed Central) - Jan 23, 2024
Anti-TIM3 antibody LY3321367 showed interesting clinical activity in combination with anti-PDL-1 antibody in patients with MSI-H cancer not previously treated with anti-PD(L)-1...In conclusion, several combination therapies of ICIs and novel strategies are emerging and may revolutionize the treatment paradigm of MSI-H patients in the future. A huge effort will be necessary to find reliable immune biomarkers to personalize therapeutical decisions.
- ||| Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Review, Journal, Adverse events, Checkpoint inhibition: Assessment of Variables Related to the Risk of Severe Adverse Events in Cutaneous Melanoma Patients Treated with Immune Checkpoint Inhibitors. (Pubmed Central) - Jan 23, 2024
Descriptive analysis did not identify any significant association between median age, gender distribution, or performance status and severe colitis, hepatitis, or pneumonitis for any of the three treatment groups. We call for greater transparency and standardization in the reporting of patient-specific irAEs.
- | Journal, Checkpoint inhibition: Distinct changes to pancreatic volume rather than pancreatic autoantibody positivity: insights into immune checkpoint inhibitors induced diabetes mellitus. (Pubmed Central) - Jan 23, 2024
ICI-DM is often accompanied by pancreatic atrophy and approximately two-thirds of patients initially present with DKA. Although the majority of ICI-DM patients lack T1DM-related autoantibodies, identifying diminished pancreatic volumes through CT imaging provides valuable clues into the subclinical aspects of ICI-DM development, aiding in the prevention of diabetic emergencies.
- || Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial primary completion date: Surgical Nivolumab And Ipilimumab For Recurrent GBM (clinicaltrials.gov) - Jan 23, 2024
P1, N=60, Recruiting, Sponsor: Patrick Wen, MD
Although the majority of ICI-DM patients lack T1DM-related autoantibodies, identifying diminished pancreatic volumes through CT imaging provides valuable clues into the subclinical aspects of ICI-DM development, aiding in the prevention of diabetic emergencies. Trial primary completion date: Dec 2023 --> Jun 2024
- | Journal: Therapeutic drug monitoring of immunotherapies with novel Affimer-NanoBiT sensor construct. (Pubmed Central) - Jan 22, 2024
After dilution of serum samples, the resulting quantifiable range for all four sensors falls within the clinically relevant range and compares favourably with the sensitivity and/or time-to-result of current ELISA standards. Further development of these sensors into a PoC test may improve treatment outcome and quality of life for patients receiving immunotherapy.
- | Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal, Metastases: Combining cabozantinib, nivolumab and ipilimumab in advanced hepatocellular carcinoma: does benefit outweigh toxicity? (Pubmed Central) - Jan 22, 2024
Further development of these sensors into a PoC test may improve treatment outcome and quality of life for patients receiving immunotherapy. No abstract available
- | Journal, Head-to-Head: The lack of head-to-head randomised trials and the consequences for patients and national health service: The case of non-small cell lung cancer. (Pubmed Central) - Jan 20, 2024
Simultaneously, the price of the drug cannot be determined correctly, relying only on indirect evaluations from different trials. To dispel this uncertainty, it would be desirable to initiate a process that brings together the demands derived from clinical practice and clinical research to provide clinicians and patients with the best possible evidence.
- | Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal, Pan tumor: Correlation between tumor size change and outcome in a rare cancer immunotherapy basket trial. (Pubmed Central) - Jan 20, 2024
P2
Percent change in tumor measurement per RECISTv1.1 (sum of longest dimensions of target lesions) has a linear association with PFS and OS up to a 40-50% increase in tumor measurement in this cohort of patients with rare cancers who received combination immune checkpoint blockade. Quantitative first scan tumor measurement changes include important information to evaluate the potential efficacy of a therapy beyond the proportion of patients who achieve an objective response.
- | Journal, Combination therapy, Metastases: Prognostic outcomes in patients with metastatic renal cell carcinoma receiving second-line treatment with tyrosine kinase inhibitor following first-line immune-oncology combination therapy. (Pubmed Central) - Jan 19, 2024
Quantitative first scan tumor measurement changes include important information to evaluate the potential efficacy of a therapy beyond the proportion of patients who achieve an objective response. There were no significant differences in the prognostic outcomes after introducing second-line TKI between the IO-IO and IO-TKI groups, and the histopathology, CRP and albumin levels had independent impacts on the prognosis in mRCC patients receiving second-line TKI, irrespective of first-line IO combination therapies.
- | Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal, Combination therapy, Real-world evidence, Real-world, Metastases, Immuno-oncology: Real-world safety of first-line immuno-oncology combination therapies for advanced non-small-cell lung cancer. (Pubmed Central) - Jan 19, 2024
There were no significant differences in the prognostic outcomes after introducing second-line TKI between the IO-IO and IO-TKI groups, and the histopathology, CRP and albumin levels had independent impacts on the prognosis in mRCC patients receiving second-line TKI, irrespective of first-line IO combination therapies. Using Flatiron Health Spotlight data, information for a pre-specified list of AEs was abstracted and described among patients with advanced NSCLC receiving 1L nivolumab
- || Opdivo (nivolumab) / Ono Pharma, BMS, Sutent (sunitinib) / Pfizer, Yervoy (ipilimumab) / Ono Pharma, BMS
Review, Journal, Metastases: The role of cytoreductive nephrectomy in the treatment of patients with metastatic kidney cancer - review article. (Pubmed Central) - Jan 19, 2024
The aim of this article is to analyse the available data, provide an up-to-date review of the literature, and discuss the controversies and challenges related to CN in patients with metastatic kidney cancer. The present literature review aims to organize and systematize the current state of knowledge, which may help in making clinical decisions regarding qualification for CN in patients with advanced kidney cancer.
- | Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal, Metastases: Combined immunotherapy with ipilimumab plus nivolumab in metastatic PD-1/PD-L1-refractory Merkel cell carcinoma-a case report. (Pubmed Central) - Jan 19, 2024
The present literature review aims to organize and systematize the current state of knowledge, which may help in making clinical decisions regarding qualification for CN in patients with advanced kidney cancer. No abstract available
- ||| Opdivo (nivolumab) / BMS, pexmetinib (ARRY-614) / Pfizer, Yervoy (ipilimumab) / BMS
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab (clinicaltrials.gov) - Jan 18, 2024
P1/2, N=70, Active, not recruiting, Sponsor: Jason J. Luke, MD
No abstract available N=144 --> 70 | Trial completion date: Jun 2027 --> Nov 2027 | Trial primary completion date: Mar 2026 --> Nov 2027 | Recruiting --> Active, not recruiting
- | Tagrisso (osimertinib) / AstraZeneca, Yervoy (ipilimumab) / BMS
Enrollment closed, Combination therapy: Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC (clinicaltrials.gov) - Jan 18, 2024
P1, N=24, Active, not recruiting, Sponsor: University of Utah
N=144 --> 70 | Trial completion date: Jun 2027 --> Nov 2027 | Trial primary completion date: Mar 2026 --> Nov 2027 | Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment closed, Trial completion date: Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer (clinicaltrials.gov) - Jan 17, 2024
P2, N=25, Active, not recruiting, Sponsor: Northwestern University
Recruiting --> Active, not recruiting Unknown status --> Active, not recruiting | Trial completion date: Jun 2022 --> Aug 2025
- | Neo Vax (NEO-PV-01) / BioNTech, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment closed: Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma (clinicaltrials.gov) - Jan 17, 2024
P1, N=20, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Unknown status --> Active, not recruiting | Trial completion date: Jun 2022 --> Aug 2025 Recruiting --> Active, not recruiting
- | CIML NK - Dana / Farber Cancer Institute
Trial completion date, Trial primary completion date, Combination therapy, Metastases, Immune cell: CIML NK Cell in Head & Neck Cancer (clinicaltrials.gov) - Jan 17, 2024
P1, N=25, Recruiting, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Active, not recruiting Trial completion date: Mar 2024 --> Jul 2024 | Trial primary completion date: Jan 2024 --> Jun 2024
- ||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Biomarker, Trial completion, Checkpoint inhibition, Tumor mutational burden, IO biomarker: BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer (clinicaltrials.gov) - Jan 16, 2024
P2, N=90, Completed, Sponsor: Lung Cancer Group Cologne
Trial completion date: Mar 2024 --> Jul 2024 | Trial primary completion date: Jan 2024 --> Jun 2024 Active, not recruiting --> Completed
- | Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal: Research hotspots and frontiers in acral melanoma: A bibliometric analysis from 1999 to 2023. (Pubmed Central) - Jan 16, 2024
This bibliometric analysis found up to 1387 publications, which not only comprehensively and quantitatively reflected the research trends and hotspots, but also provided a theoretical basis for future studies of AM. Researchers can benefit from choosing the right journals and finding potential collaborators or partner institutions.
- || Yervoy (ipilimumab) / Ono Pharma, BMS
Review, Journal: Short-chain fatty acids (SCFAs) from gastrointestinal disorders, metabolism, epigenetics, central nervous system to cancer - A mini-review. (Pubmed Central) - Jan 15, 2024
This mini-review explores SCFAs' diverse roles, shedding light on their significance in health and potential implications for disease management. Understanding SCFAs' intricate mechanisms enhances our knowledge of their therapeutic potential and highlights their emerging importance in various physiological contexts.
- Papillary Renal Cell Carcinoma (pRCC): Outcomes Of Patients Receiving First-Line Immune-Based Combinations Or Tyrosine Kinase Inhibitors (TKIs) From The ARON-1 StudyPapillary Renal Cell Carcinoma (pRCC): Outcomes Of Patients Receiving First-Line Immune-Based Combinations Or Tyrosine Kinase Inhibitors (TKIs) From The ARON-1 Study (N04) - Jan 15, 2024 - Abstract #EAU2024EAU_2971;
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Real clinical outcomes of nivolumab plus ipilimumab for renal cell carcinoma in patients over 75 years old (N04) - Jan 15, 2024 - Abstract #EAU2024EAU_2967;
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Prognostic factors for overall survival (OS) in patients receiving first-line (1L) nivolumab plus ipilimumab (NIVO+IPI) for advanced/metastatic renal cell carcinoma (aRCC) in a real-world setting in Germany (N04) - Jan 15, 2024 - Abstract #EAU2024EAU_2965;
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Outcome of patients with synchronous metastatic renal cell carcinoma treated with nivolumab and ipilimumab and the primary tumour in place (N04) - Jan 15, 2024 - Abstract #EAU2024EAU_2962;
- Delayed partial nephrectomy following complete response to immunotherapy: feasibility and results (UroCCR n (N04) - Jan 15, 2024 - Abstract #EAU2024EAU_2960;
- | Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal: Pediatric model-based dose optimization using a pooled exposure-response safety analysis for nivolumab and nivolumab plus ipilimumab combination in melanoma. (Pubmed Central) - Jan 15, 2024
These results also support adult weight-based dosing regimens for nivolumab plus ipilimumab in adolescents with advanced melanoma. This analysis suggests that although higher exposures are predicted in adolescents with lower weight compared with adults, there is no predicted immune-mediated safety risk when treated with the approved adult dosing of nivolumab with/without ipilimumab.
- || Review, Journal, Checkpoint inhibition: Onset of Psoriasis with Immune Checkpoint Inhibitor Therapy: A Systematic Review. (Pubmed Central) - Jan 15, 2024
This analysis suggests that although higher exposures are predicted in adolescents with lower weight compared with adults, there is no predicted immune-mediated safety risk when treated with the approved adult dosing of nivolumab with/without ipilimumab. No abstract available
- || Cabometyx (cabozantinib tablet) / Exelixis
Trial completion date, Trial primary completion date: Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Jan 11, 2024
P2, N=105, Active, not recruiting, Sponsor: Washington University School of Medicine
No abstract available Trial completion date: Aug 2027 --> Aug 2028 | Trial primary completion date: Feb 2024 --> Feb 2025
- || Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion date: A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650) (clinicaltrials.gov) - Jan 11, 2024
P2, N=351, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial completion date: Aug 2027 --> Aug 2028 | Trial primary completion date: Feb 2024 --> Feb 2025 Trial completion date: Oct 2026 --> May 2024
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion date, Trial primary completion date, Checkpoint inhibition, IO biomarker: NEOSTAR: Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer (clinicaltrials.gov) - Jan 11, 2024
P2, N=101, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Oct 2026 --> May 2024 Trial completion date: Jul 2024 --> Dec 2024 | Trial primary completion date: Jul 2024 --> Dec 2024
- ||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial termination, Monotherapy: CheckMate 74W: A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer (clinicaltrials.gov) - Jan 11, 2024
P3, N=26, Terminated, Sponsor: Bristol-Myers Squibb
Trial completion date: Jul 2024 --> Dec 2024 | Trial primary completion date: Jul 2024 --> Dec 2024 Active, not recruiting --> Terminated
- | Trial completion date, Surgery, Metastases: Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery (clinicaltrials.gov) - Jan 11, 2024
P2, N=169, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Terminated Trial completion date: Mar 2024 --> Jan 2025